creatine has been researched along with Autosomal Dominant Cerebellar Ataxia, Type II in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Autosomal dominant ataxia type 14 (SCA14) is a rare usually adult-onset progressive disorder with cerebellar neurodegeneration caused by mutations in protein kinase C gamma." | 1.42 | Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. ( Brandt, AU; Doss, S; Endres, M; Klockgether, T; Lux, S; Maul, S; Minnerop, M; Papazoglou, S; Paul, F; Rinnenthal, JL; Schmitz-Hübsch, T; Würfel, J, 2015) |
| "Autosomal-dominant spinocerebellar ataxia type 1 (SCA1) is an adult-onset progressive disorder with well-characterized neurodegeneration in the cerebellum and brainstem." | 1.40 | Metabolic evidence for cerebral neurodegeneration in spinocerebellar ataxia type 1. ( Brandt, AU; Doss, S; Endres, M; Oberwahrenbrock, T; Paul, F; Rinnenthal, JL, 2014) |
| "We reported a Japanese case of spinocerebellar ataxia type 6 (SCA6) with episodic ataxia type 2 (EA2) phenotype." | 1.33 | [A case of spinocerebellar ataxia type 6 with its initial symptom of episodic ataxia-like phenotype]. ( Ishikawa, K; Nakano, I; Nakao, K; Shimazaki, H; Takiyama, Y, 2006) |
| "Compared with control subjects, the SCA1 and SCA2 patients showed a decrease (P < 0." | 1.32 | Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. ( Belli, G; Cosottini, M; De Grandis, D; Della Nave, R; Filla, A; Foresti, S; Ginestroni, A; Guerrini, L; Lolli, F; Mascalchi, M; Piacentini, S; Plasmati, R; Salvi, F; Siciliano, G; Tessa, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doss, S | 2 |
| Brandt, AU | 2 |
| Oberwahrenbrock, T | 1 |
| Endres, M | 2 |
| Paul, F | 2 |
| Rinnenthal, JL | 2 |
| Schmitz-Hübsch, T | 1 |
| Papazoglou, S | 1 |
| Lux, S | 1 |
| Maul, S | 1 |
| Würfel, J | 1 |
| Klockgether, T | 1 |
| Minnerop, M | 1 |
| Wang, PS | 1 |
| Chen, HC | 1 |
| Wu, HM | 1 |
| Lirng, JF | 1 |
| Wu, YT | 1 |
| Soong, BW | 1 |
| Guerrini, L | 1 |
| Lolli, F | 1 |
| Ginestroni, A | 1 |
| Belli, G | 1 |
| Della Nave, R | 1 |
| Tessa, C | 1 |
| Foresti, S | 1 |
| Cosottini, M | 1 |
| Piacentini, S | 1 |
| Salvi, F | 1 |
| Plasmati, R | 1 |
| De Grandis, D | 1 |
| Siciliano, G | 1 |
| Filla, A | 1 |
| Mascalchi, M | 1 |
| Harno, H | 1 |
| Heikkinen, S | 1 |
| Kaunisto, MA | 1 |
| Kallela, M | 1 |
| Häkkinen, AM | 1 |
| Wessman, M | 1 |
| Färkkilä, M | 1 |
| Lundbom, N | 1 |
| Shimazaki, H | 1 |
| Nakao, K | 1 |
| Ishikawa, K | 1 |
| Takiyama, Y | 1 |
| Nakano, I | 1 |
| Boesch, SM | 2 |
| Wolf, C | 1 |
| Seppi, K | 1 |
| Felber, S | 2 |
| Wenning, GK | 1 |
| Schocke, M | 2 |
| Kaemmerer, WF | 1 |
| Rodrigues, CM | 1 |
| Steer, CJ | 1 |
| Low, WC | 1 |
| Bürk, K | 1 |
| Hollosi, P | 1 |
| Fornai, F | 1 |
| Aichner, FT | 1 |
| Poewe, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for creatine and Autosomal Dominant Cerebellar Ataxia, Type II
| Article | Year |
|---|---|
Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging.
Topics: Adult; Age of Onset; Aged; Aspartic Acid; Cerebellum; Choline; Creatine; Diagnosis, Differential; Fe | 2007 |
8 other studies available for creatine and Autosomal Dominant Cerebellar Ataxia, Type II
| Article | Year |
|---|---|
Metabolic evidence for cerebral neurodegeneration in spinocerebellar ataxia type 1.
Topics: Adult; Aged; Analysis of Variance; Aspartic Acid; Brain; Cerebral Cortex; Choline; Creatine; Female; | 2014 |
Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency.
Topics: Adult; Aged; Aspartic Acid; Cerebellum; Cerebral Cortex; Creatine; Female; Glutamic Acid; Glutathion | 2015 |
Association between proton magnetic resonance spectroscopy measurements and CAG repeat number in patients with spinocerebellar ataxias 2, 3, or 6.
Topics: Adult; Age of Onset; Aged; Aspartic Acid; Case-Control Studies; Cerebellum; Creatine; Disease Progre | 2012 |
Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study.
Topics: Adult; Aged; Aspartic Acid; Biomarkers; Brain Stem; Cerebellum; Creatine; Female; Humans; Magnetic R | 2004 |
Decreased cerebellar total creatine in episodic ataxia type 2: a 1H MRS study.
Topics: Adolescent; Adult; Aspartic Acid; Calcium Channels; Cerebellum; Child; Choline; Creatine; Dysarthria | 2005 |
[A case of spinocerebellar ataxia type 6 with its initial symptom of episodic ataxia-like phenotype].
Topics: Adult; Aspartic Acid; Brain Chemistry; Creatine; Female; Humans; Magnetic Resonance Imaging; Magneti | 2006 |
Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype.
Topics: Animals; Ataxin-1; Ataxins; Bile Acids and Salts; Cell Count; Cell Survival; Cerebellum; Creatine; D | 2001 |
Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6.
Topics: Adult; Aspartic Acid; Choline; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; Male; Midd | 2001 |